Ferinject Injection 50Mg/Ml 10Ml
Brand : obs pakistan pvt. ltd
Requires Prescription (YES/NO)
How it works
Ferric Carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.
USAGE AND SAFETY
Common: Nausea, dizziness, gastrointestinal disturbances, headache, injection site reactions, rash, hypophosphatemia, hypertension. Uncommon: Anaphylaxis, arthralgia, back pain, chest pain, fatigue, flushing, hypotension, malaise, tachycardia, myalgia, paraesthesia, dysgeusia, peripheral oedema, chills, pruritus, pyrexia, rigors, urticaria. Rare: Dyspnoea, loss of consciousness, anxiety, phlebitis, syncope, flatulence, pallor.
The absorption of oral iron is reduced when administered concomitantly with parenteral iron preparations. Therefore, if required, oral iron therapy should not be started for at least 5 days after the last injection of Ferric Carboxymaltose.
Ferric Carboxymaltose Injection is indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron & who have non-dialysis dependent chronic kidney disease.
When not to Use
Known hypersensitivity to the active substance, or any of its excipients or serious hypersensitivity to other parenteral iron products, anemia not attributed to iron deficiency, e.g. other microcytic anemia and evidence of iron overload or disturbances in the utilisation of iron.
Parenteral iron must be used with caution in case of acute or chronic infection, asthma, eczema or atopic allergies. It is recommended that the treatment with Ferric Carboxymaltose is stopped in patients with ongoing bacteremia .
Caution should be exercised to avoid paravenous leakage when administering Ferric Carboxymaltose. Paravenous leakage of Ferric Carboxymaltose at the injection site may lead to irritation of the skin and potentially long lasting brown discoloration at the site of injection. In case of paravenous leakage, the administration of Ferric Carboxymaltose must be stopped immediately.
Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes. The risk is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.
In patients with liver dysfunction, parenteral iron should only be administered after careful benefit/risk assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.